Mar 28, 2022 8:30am EDT Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
Mar 24, 2022 8:30am EDT Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference
Jan 13, 2022 8:30am EST Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors
Nov 19, 2021 8:30am EST Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
Nov 17, 2021 8:00am EST Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea
Nov 15, 2021 4:01pm EST Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 12, 2021 8:00am EST Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
Nov 11, 2021 6:00am EST Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions
Oct 18, 2021 4:01pm EDT Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
